News

Ng et al detected anti-NF155 IgG1 and/or IgG3 antibodies at low frequency in patients with AIDP (3/65) and CIDP (5/119). 66 This was followed by the detection of a similar proportion of IgG4 ...
Immunotherapy led to complete resolution of tongue stiffness and recovery of limb power. Literature is emerging, associating anti-GAD65Ab with autoimmune neuropathies like Acute Inflammatory ...
Sanofi's antibody riliprubart has received orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare (MHLW) for its potential to treat chronic inflammatory demyelinating ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE ...
Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European Commission/EC approved VYVGART (efgartigimod alfa) 1000mg for subcutaneous ...
Find the latest Neurology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.
Telehealth neurological services are already available at Helen Keller Hospital. That means the on-call neurologist at Huntsville Hospital can help consult with patients from 75 miles away.
An anti-inflammatory diet was associated with lower dementia risk in adults with cardiometabolic diseases. Over 12 years, dementia risk was 31% lower for those who followed an anti-inflammatory ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's ...